Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II

Executive Summary

Roche's development plans for a follow-on Avastin product have been called into question after the company noted briefly in its third-quarter earnings update that the drug failed in a Phase II study in colorectal cancer patients.

Advertisement

Related Content

MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA
ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register